Verastem, Inc.
VSTMHealthcare|Biotechnology|US
$8.41
-0.97 (-10.34%)
Cash / Share
$1.71
Clinical Trials (50)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06072781 A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Low Grade Serous Ovarian Cancer | P3 | Recruiting | 270 | RCT, Open-label | avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole, Anastrozole |
| NCT04331041 Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | Pancreas Cancer, Cancer of the Pancreas | P2 | Active | 42 | RCT, Open-label | Defactinib |
| NCT07659795 A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | Colorectal Cancer | P2 | Recruiting | 150 | RCT, Single-blind | VS-7375, cetuximab, panitumumab, Cetuximab + mFOLFOX6 |
| NCT06194929 Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | Cutaneous Melanoma, Brain Metastases | P1P2 | Recruiting | 33 | Open-label | Defactinib, Avutometinib, Encorafenib |
| NCT06394804 A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | Low-Grade Serous Ovarian Cancer | P2 | Recruiting | 20 | Open-label | Avutometinib, Defactinib, Letrozole |
| NCT05608252 VS-6766+Abema+Fulv in Met HR+/HER- BC | Breast Cancer, Hormone Receptor-positive Breast Cancer | P1P2 | Recruiting | 63 | Open-label | VS-6766, Abemaciclib, Fulvestrant |
| NCT07020221 A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer | P1P2 | Recruiting | 616 | Open-label | VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab, Defactinib, Midazolam, Repaglinide |
| NCT05074810 Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients | Non Small Cell Lung Cancer, KRAS Activating Mutation | P1P2 | Active | 153 | Open-label | avutometinib and sotorasib, avutometinib and sotorasib and defactinib |
| NCT05669482 Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | KRAS Activating Mutation, Metastatic Cancer | P1P2 | Active | 40 | Open-label | avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel |
| NCT07659782 A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | P2 | Recruiting | 105 | RCT, Single-blind | VS-7375 |
| NCT06007924 A Study of Avutometinib and Defactinib in People With Thyroid Cancer | Thyroid Cancer | P2 | Recruiting | 30 | Open-label | Avutometinib, Defactinib |
| NCT06487221 Avutometinib and Defactinib in Diffuse Gastric Cancer | Gastric Cancer, Stomach Cancer | P2 | Recruiting | 27 | Open-label | Avutometinib, Defactinib |
| NCT06630260 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours | Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma) | P1P2 | Recruiting | 182 | Open-label | Avutometinib, Defactinib, Temozolomide |
| NCT07644559 A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS | P2 | Recruiting | 185 | RCT, Single-blind | VS-7375, cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction) |
| NCT04625270 A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation | Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | P2 | Active | 225 | RCT, Open-label | avutometinib (VS-6766), avutometinib (VS-6766) and defactinib |
| NCT06682572 A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients | Low Grade Serous Ovarian Cancer, Ovarian Cancer | P2 | Active | 16 | Open-label | Avutometinib (VS-6766) + Defactinib (VS-6063) |
| NCT05787561 A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer | Mesonephric Gynecologic Cancer | P2 | Active | 40 | Open-label | Avutometinib (VS-6766), Defactinib |
| NCT07126158 Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma, Cancer of the Pancreas | P2 | Recruiting | 36 | RCT, Open-label | Defactinib, Avutometinib |
| NCT05512208 A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib | Endometrioid Cancer, Mucinous Ovarian Cancer | P2 | Recruiting | 55 | Open-label | Avutometinib (VS-6766) + defactinib |
| NCT07318324 Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer | Phase IB, Avutometinib | P1 | Recruiting | 31 | Open-label | Avutometinib, defactinib, Everolimus |
| NCT03875820 Phase I Trial of Defactinib and VS-6766. | NSCLC, Low Grade Serous Ovarian Cancer | P1 | Active | 87 | Open-label | VS-6766, Defactinib |
| NCT05798507 Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | Glioblastoma, Recurrent Glioblastoma | Early P1 | Active | 14 | Open-label | Avutometinib, Defactinib |
| NCT02758587 Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | Carcinoma, Non-small-cell Lung, Mesothelioma | P1P2 | Unknown | 59 | Open-label | Defactinib, Pembrolizumab |
| NCT05375994 Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients | Non Small Cell Lung Cancer, KRAS Activating Mutation | P1P2 | Completed | 12 | Open-label | avutometinib (VS-6766) and adagrasib |
| NCT07824960 Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma | Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | P1P2 | Not Yet Recruiting | 31 | Open-label | Avutometinib (VS-6766) + Defactinib (VS-6063) |
| NCT04620330 A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer, KRAS Activating Mutation | P2 | Completed | 90 | RCT, Open-label | avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib |
| NCT05200442 A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | Colorectal Cancer, Colorectal Adenocarcinoma | P1P2 | SUSPENDED | 53 | Open-label | VS-6766/avutometinib, Cetuximab |
| NCT02004028 Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants | Malignant Pleural Mesothelioma | P2 | Terminated | 35 | Open-label | VS-6063 |
| NCT04487886 Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19) | COVID-19 | P2 | Completed | 47 | RCT, Double-blind | Duvelisib, Placebo |
| NCT03727880 Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma | P2 | Completed | 28 | RCT, Open-label | Pembrolizumab, Defactinib |
| NCT03287271 ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK | Ovarian Cancer | P1P2 | Terminated | 8 | Open-label | VS-6063, Paclitaxel, Carboplatin |
| NCT07747506 Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | P2 | Not Yet Recruiting | 2 | Open-label | avutometinib + defactininb combination |
| NCT04720417 Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma | Metastatic Uveal Melanoma | P2 | Terminated | 13 | Open-label | Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766 |
| NCT01951690 Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer, Lung Cancer | P2 | Completed | 55 | Open-label | defactinib (VS-6063) |
| NCT01870609 Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma | Malignant Pleural Mesothelioma | P2 | Terminated | 344 | RCT, Double-blind | defactinib (VS-6063), Placebo |
| NCT04372602 Duvelisib to Combat COVID-19 | COVID-19 | P2 | Completed | 28 | RCT, Double-blind | Duvelisib, Placebo |
| NCT02546531 Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer | Advanced Solid Tumors, Solid Tumors | P1 | Completed | 43 | Open-label | Defactinib, Pembrolizumab, Gemcitabine |
| NCT00666926 Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms | Head and Neck Neoplasm, Prostatic Neoplasm | P1 | Completed | 99 | Open-label | PF00562271, PF00562271, PF00562271, PF00562271 |
| NCT02372227 A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma | Relapsed Malignant Mesothelioma | P1 | Terminated | 21 | Open-label | VS-5584 and VS-6063 |
| NCT01849744 Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies | Non Hematologic Cancers, Metastatic Cancer | P1 | Terminated | 48 | Open-label | VS-4718 |
| NCT02651727 Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects | Pancreatic Cancer | P1 | Terminated | 13 | RCT, Open-label | Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine, Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine, Part A- VS-4718, nab-paclitaxel, gemcitabine |
| NCT02407509 Phase I Trial of VS-6766 Alone and in Combination With Everolimus | Solid Tumours, Multiple Myeloma | P1 | Completed | 104 | Open-label | VS-6766, Everolimus |
| NCT01991938 Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma | Non Hematologic Cancers, Metastatic Cancer | P1 | Terminated | 75 | Open-label | VS-5584 |
| NCT00787033 A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies | Cancer | P1 | Completed | 46 | Open-label | PF-04554878 |
| NCT01778803 Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer | Ovarian Cancer | P1 | Completed | 22 | Open-label | defactinib, Paclitaxel |
| NCT02913716 A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects | Healthy Subjects | P1 | Completed | 5 | Open-label | defactinib |
| NCT01943292 Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies | Non Hematologic Cancers | P1 | Completed | 9 | Open-label | Defactinib |
| NCT02943317 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer | Epithelial Ovarian Cancer | P1 | Terminated | 98 | Open-label | Part A - VS-6063, Part A - Avelumab |
| NCT02215629 Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | P1 | Withdrawn | — | Open-label | VS-4718 |
| NCT05187169 Food Effect of VS-6766 in Healthy Adult Subjects | Food Effect | P1 | Completed | 18 | RCT, Open-label | VS-6766 |